News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
Amol Akhade: Aumolertinib and Chemotherapy, A New Challenger to Osimertinib?
Amol Akhade/LinkedIn
Apr 30, 2025, 10:53

Amol Akhade: Aumolertinib and Chemotherapy, A New Challenger to Osimertinib?

Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on LinkedIn:

“Aumolertinib and Chemotherapy: A New Challenger to Osimertinib? (Insights from AACR25)

The landscape of first-line treatment for EGFR-mutant NSCLC continues to evolve!

At AACR2025, the AENEAS2 trial evaluating Aumolertinib and Platinum–Pemetrexed showcased remarkable results:

Median PFS:

  • Aumolertinib and Chemo: 28.9 months.
  • Aumolertinib Monotherapy: 18.9 months.
  • (HR 0.47, 95% CI 0.37–0.60).

Early OS trend:

  • Hazard Ratio for Overall Survival: 0.44.
  • (Median OS not yet reached).

Strong Subgroup Benefits:

Consistent efficacy across gender, smoking history, ECOG PS, CNS metastases, and EGFR mutation types (Ex19del and L858R). Especially powerful in younger patients, smokers, and Exon19 deletion patients.

CNS Metastasis Control:

Maintained with a Hazard Ratio of 0.56 for patients with baseline brain mets.

Comparison with FLAURA2 (Osimertinib and Chemo):

Median PFS:

  • Aumolertinib and Chemo = 28.9 months (HR 0.47).
  • Osimertinib and Chemo = 25.5 months (HR 0.62).

Overall Survival Trend:

  • Aumolertinib and Chemo = HR 0.44 (early strong signal).
  • Osimertinib and Chemo = HR ~0.79 (not statistically significant yet).

CNS Metastases Control:

  • Aumolertinib = HR 0.56
  • Osimertinib = HR ~0.58

Population:

  • Aumolertinib trial = 100% Asian.
  • Osimertinib trial = Global (~62% Asian).

Key Takeaways:

Aumolertinib and Chemo is setting a new bar for PFS in EGFR-mutant NSCLC.

Early OS signals appear stronger than in FLAURA2. Subgroup consistency and CNS activity are both encouraging.

Pending: Full quality of life and global applicability data.”

Amol Akhade: Aumolertinib and Chemotherapy, A New Challenger to Osimertinib?

More posts featuring Amol Akhade.

AACR25 AENEAS2 trial Amol Akhade Aumolertinib cancer chemotherapy CNS metastases ECOG PS EGFR fight against cancer FLAURA2 Global fight against cancer NSCLC OncoDaily Oncology osimertinib PFS Reliance Hospitals Suyog Cancer Clinics
Special Coverage
Blog
Apr 30, 2025, 10:53
Amol Akhade: Aumolertinib and Chemotherapy, A New Challenger to Osimertinib?
Science
Apr 30, 2025, 10:42
George Vlachogiannis: Modified Glasgow Prognostic Score can reliably predict osteoporosis risk in elderly cancer patients
Blog
Apr 30, 2025, 10:36
Douglas Flora: Don’t Let AI Make You Irrelevant - Start Preparing Today
Science
Apr 30, 2025, 10:26
Herbert Loong: Promising data on D3S-001 at AACR25
Blog
Apr 30, 2025, 10:19
Eric Singhi: Very excited to join this year’s LUNGevity Foundation HOPE Summit
Blog
Apr 30, 2025, 10:11
Patricia M. LoRusso and Robin Zon co-moderated AACR - ASCO Joint Session at AACR25
Blog
Apr 30, 2025, 10:10
Giuseppe Lombardi: Registration is open for the International Congress in Neuro-Oncology in Padova
Science
Apr 30, 2025, 10:10
Maryam Lustberg: Editorial on the unmets breast cancer survivors and menopause
Blog
Apr 30, 2025, 10:03
Kevin Manemann: I'm excited to announce that I'm leading a session this July at the ACHE Boston Cluster
Insight
Apr 30, 2025, 09:58
Nathan Pennell: ASCO25 review on the emerging role of MDTs
Blog
Apr 30, 2025, 09:55
Amol Akhade: Next-generation KRAS G12C inhibitors are reshaping precision oncology
Science
Apr 30, 2025, 09:45
Kunal Jobanputra: Zongertinib in HER2-mutant NSCLC